Clinical experiences concerning the intramuscular contraceptive oxogestone.
91 patients (age 20-35) were treated with 50 mg oxogestone (20-beta-hydroxy-delta-4-19-nor-pregnene-3-on) injected intramuscularly on the last day of menstruation for 462 cycles. Oxogestone prevented ovulation since by Day 8 following treatment pregnanediol excretion was 1/5 control values. The 44 bleeding complications were primarily among the group of 51 women who had prior use of contraception. 6 of the 14 pregnancies which occurred were due to patient negligence. Other complications included headache, weight gain, urticaria, mastodynia, and change in libido. No thromboembolic phenomena was observed.